Loading stock data…
Attovia Therapeutics, Inc. (ATTO)
$23.66-1.89 (-7.40%)
Market ClosedLast close Sep 8
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States.
Historical Price
Price (Candle)
Synthesizing Whystock Narrative...
Quarterly Financials
| Metric (USD) | Q1 2026 | Q1 2025 |
|---|---|---|
| Total Revenue | $0 | $0 |
| Gross Profit | — | — |
| Operating Income | -$19.95M↓ | -$16.10M |
| Net Income | -$18.66M↓ | -$15.15M |
Peer Comparison
JNJUNHPFE
Fundamentals
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatment...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.08B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
26.93%
Volume
Today's trading volume
267,433
Recent News
Attovia Therapeutics Could Serve as Key Player in Immunology, Inflammation, RBC Says
Attovia Therapeutics' (ATTO) ATTOBODY platform should position the company as a key player in immuno
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Deere upgraded, Lumentum initiated: Wall Street's top analyst calls
Here Are Monday’s Top Wall Street Analyst Research Calls: AGCO Corporation, Deere & Co., Edison International, Lumentum Holdings, PG&E, Sempra Energy, STAG Industrial, Ticketplus, and More
Rate hike fears rattled markets heading into the Labor Day weekend, and Wall Street analysts responded with a flurry of bold calls on utilities, farm equipment giants, and a ticketing upstart that could reshape your portfolio heading into a volatile fall.
Moderna Stock Carries A Market Value Its Revenue Does Not Support
Moderna's commercial business has shrunk and is lossmaking, which puts the weight of its market value on a pipeline rather than on revenue.
Moderna Stock Had A Readout Waiting In Plain Sight
Before the melanoma result, the visible signs were an enrolled trial, a partner paying half its cost, and a market that had stopped pricing an unusually large move.